Evercore ISI Group Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $146
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Evercore ISI Group analyst Gavin Clark-Gartner maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $135 to $146.
Evercore ISI Group analyst Gavin Clark-Gartner maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $135 to $146.